Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

Hepatology

Volumn 28, Issue 6, 1998, Pages 1669-1673

  Xiong, Xiaofeng ^a   Flores, Carmina ^a   Yang, Huiling ^a   Toole, John J ^a   Gibbs, Craig S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; DNA DIRECTED DNA POLYMERASE; LAMIVUDINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CROSS RESISTANCE; DRUG EFFICACY; EXPRESSION VECTOR; GENE MUTATION; HEPATITIS B; IMMUNOAFFINITY CHROMATOGRAPHY; INHIBITION KINETICS; MICHAELIS CONSTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 0031793849     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280629     Document Type: Article

References (19)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
3. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
4. Lai CL, Liaw YF, Leung NWY, Deslauriers M, Barnard J, Sanathanan L, Gray DF, et al. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters [Abstract]. HEPATOLOGY 1997;26(Suppl4):259A.
5. Leung NWY, Lai CL, Liaw YF, Chang TT, Guan R, Tai Dl, Ng KY, et al. Lamivudine (100 mg od) for 1 year significantly improves necroinflammatory activity and reduces progression in fibrosis stage: results of a placebo-controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection. [Abstract]. HEPATOLOGY 1997;26(Suppl4):357A.
6. Tanikawa K, Hayashi N, Ichida F, Lino S, Kumada H, Ogawa N, Okida K, et al. A placebo-controlled phase III study of lamivudine in Japanese patients with chronic hepatitis B infection [Abstract]. HEPATOLOGY 1997;26(Suppl4):259A.
7. Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996;3:211-215.
8. Gilson RJ, Chopra K, Murray-Lyon IM, Newell AM, Nelson MR, Tedder RS, Toole JJ, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection [Abstract]. HEPATOLOGY 1996;24(Suppl4):281A.
9. Jeffers L, Heathcote E, Wright T, Carithers R, di Bisceglie A, Perrillo R, Rustgi V, et al. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection [Abstract] Antiviral Res 1998;37:A197.
10. Bloomer J, Chan R, Sherman M, Ingraham P, DeHertogh D. A preliminary study of lobucavir for chronic hepatitis B [Abstract]. HEPATOLOGY 1997;26(Suppl4):428A.
11. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-1448.
12. De Clercq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides 1994;13:1271-1295.
13. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8:261-272.
14. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464-467.
15. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holly A, et al. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988;32:1025-1030.
16. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol 1997;26:1393-1395.
17. Bartholomew MM, Jansen RW, Jeffers LJ, Rajender Reddy K, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
18. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dushheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. HEPATOLOGY 1996;24:711-713.
19. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;24:714-717.